Disease Synopsis
Overview
Drugs and Clinical Candidates
Clinical Trials (visual)
Clinical Trials (text)
Cell Line Models
Chemistry

Oesophageal Cancer - Overview - Disease Synopsis

Drugs & Clinical Candidates


5 drugs have received FDA approval for Oesophageal Cancer . Docetaxel, Pembrolizumab, Ramucirumab, Trastuzumab and Trifluridine
0 drugs have a clinical trial registered for Oesophageal Cancer.

Sources: cancer.gov and clinicaltrials.gov
(see details)

Clinical Trials


There are 0 clinical trials for Oesophageal Cancer,
0 of which have one or more drug interventions,
0 with no drug intervention.

Sources: cancer.gov and clinicaltrials.gov
(see details)

Cell Line Models


There are 7 Cell Line Models for Oesophageal Cancer.

Source: COSMIC
(see details)

Chemistry


There are 47 Compounds which have been tested in Oesophageal Cancer , 44 <= 500nM potency.

Source: ChEMBL
(see details)

Mappings


Please note the mappings below are based on an imperfect algorithm. If you notice any anomalies please report them to us.

The following terms have been mapped from clinicaltrials.gov mesh condition terms to Oesophageal Cancer:


The following terms have been mapped from cancer.gov to Oesophageal Cancer:
Gastric (stomach) cancer or gastroesophageal junction cancer that is recurrent and either locally advanced or metastatic. It is used in patients whose cancer has the PD-L1 protein and whose disease got worse during or after two or more types of treatment including a fluoropyrimidine and platinum chemotherapy and, in some cases, HER2/neu targeted therapy.????
Stomach adenocarcinoma or gastroesophageal junction adenocarcinoma (a rare type of esophageal cancer) that has metastasized. It is used in adults who have already received at least two treatments with a fluoropyrimidine and platinum chemotherapy and either a taxane or irinotecan and, in some cases, HER2/neu-targeted therapy
Stomach adenocarcinoma or gastroesophageal junction adenocarcinoma (a rare type of esophageal cancer) that has metastasized. It is used in patients whose disease is HER2+. This use is approved for the Herceptin and Ogivri brands of trastuzumab
Stomach adenocarcinoma or gastroesophageal junction adenocarcinoma (a rare type of esophageal cancer) that is advanced or has metastasized (spread to other parts of the body). It is used in patients whose disease has gotten worse after treatment with a fluoropyrimidine or platinum chemotherapy. It is used alone or with paclitaxel
Stomach adenocarcinoma or gastroesophageal junction adenocarcinoma (a rare type of esophageal cancer) that is advanced. It is used in patients whose disease has not been treated with chemotherapy